No Data
No Data
Shanxi C&Y Pharmaceutical Group (300254.SZ): Subsidiary received an invention patent certificate.
On July 8th, Glodon News reports that Shanxi C&Y Pharmaceutical Group (300254.SZ) announced that its subsidiary, Jiangsu Jia Yi Pharmaceutical Co., Ltd., recently received a patent certificate for the invention of the preparation method of a new γ-crystalline enalapril arginine salt from the National Intellectual Property Office.
Shanxi C&Y Pharmaceutical Group (300254.SZ): The currently available vitamin product sold by the company is Vitamin AD Drops.
On June 27th, Gelonhui reported that an investor asked Shanxi C&Y Pharmaceutical Group (300254.SZ) on the investor interaction platform, 'What kinds of vitamin products does your company have?' The company replied that the currently available vitamin product is Vitamin AD Drops.
Currently shanxi c&y pharmaceutical group (300254.SZ) has not obtained any product foreign listing licenses in countries such as the USA or Europe.
On June 26, Gelunhui reported that an investor asked Shanxi C&Y Pharmaceutical Group on the investor interaction platform, "What products have your company obtained foreign market approval, such as in the United States or Europe?" The company replied that currently, the company has no products that have obtained foreign market approval in the United States or Europe, and the company's products are mainly sold domestically.
Shanxi C&Y Pharmaceutical Group (300254.SZ) received a government subsidy of RMB 4 million.
On June 7th, Glon Hui reported that Shanxi C&Y Pharmaceutical Group (300254.SZ) received a special fund totaling 4 million yuan for the consistency evaluation award of the generic salt succinate tablets for technical renovation in 2024 from the Finance Bureau of Datong Economic and Technological Development Zone.
Shanxi C&Y Pharmaceutical Group (300254.SZ) granted 7.05 million restricted stocks to 50 incentive targets.
Shanxi C&Y Pharmaceutical Group (300254.SZ) announced on June 3rd that the restricted stock incentive plan for 2024 has established the conditions for granting restricted stock rights, and agreed to designate the grant date as June 3, 2024. A total of 7.05 million restricted stocks will be granted to 50 incentive recipients who meet the granting conditions at a grant price of 4.73 yuan per share.
ShanXi C&Y Pharmaceutical Group Co.,LTD. (SZSE:300254) Stock Rockets 36% As Investors Are Less Pessimistic Than Expected
ShanXi C&Y Pharmaceutical Group Co.,LTD. (SZSE:300254) shares have continued their recent momentum with a 36% gain in the last month alone. Looking back a bit further, it's encouraging to see the s
No Data